Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Hangzhou Just Biotherapeutics In-licenses China Rights to Bone Disease Biotherapies from Lilly

publication date: Mar 29, 2019

Transcenta Holding announced that its Hangzhou Just Biotherapeutics subsidiary in-licensed China rights to a portfolio of novel bone disease biotherapeutics from Eli Lilly. In January 2019, HJB joined with MabSpace, a Suzhou mAb development company, to form Transcenta. As part of the Lilly portfolio, HJB acquired rights to blosozumab, an antibody to sclerostin being developed as an osteoporosis treatment. Lilly will receive an upfront payment in cash plus equity in Transcenta. It will also be eligible for regulatory and sales milestones, plus royalties. More details....

Stock Symbol: (NYSE:LLY)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.